Colchicine for acute and chronic coronary syndromes

  title={Colchicine for acute and chronic coronary syndromes},
  author={Massimo Imazio and A. Andreis and Antonio Luca Brucato and Yehuda Adler and Gaetano Maria De Ferrari},
  pages={1555 - 1560}
Colchicine is an ancient drug, traditionally used for the treatment and prevention of gouty attacks; it has become standard of treatment for pericarditis with a potential role in the treatment of coronary artery disease. Atherosclerotic plaque formation, progression, destabilisation and rupture are influenced by active proinflammatory cytokines interleukin (IL)-1β and IL-18 that are generated in the active forms by inflammasomes, which are cytosolic multiprotein oligomers of the innate immune… 

Figures and Tables from this paper

Colchicine for the Treatment of Coronary Artery Disease.
Colchicine in patients with coronary heart disease: new possibilities in reduction of the residual inflammatory risk
Results of studies devoted to the use of colchicine in chronic and acute coronary syndrome are presented, including the key ones LoDoCo2 (2020) and COLCOT (2019) which provided evidence of the effect of the drug on the disease outcome.
The Role of the Inflammasome in Heart Failure
The present review summarizes the recent advances in both basic and clinical research on the role of the inflammasome in HF and suggests that it is a critical mediator of cardiac inflammation during HF and a promising therapeutic target.
Colchicine efficacy and safety for the treatment of cardiovascular diseases
Colchicine is efficacious and safe for the treatment of cardiovascular diseases and associated with increased risk of gastrointestinal CRAEs and drug discontinuation.
Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes
In this review, the successes and existing doubts of interleukin 1β antibodies, interLEukin 6 receptor antagonists, and colchicine in the anti-inflammatory treatment of coronary atherosclerotic heart disease are summarized.
Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta‐Analysis of Randomized Trials
Among patients with CAD, colchicine reduces the risk of myocardial infarction and stroke, but has a higher rate of gastrointestinal upset with no influence on all-cause mortality.
Anti-inflammatory Therapy in Atherosclerosis: The Past and the Future
It was not until the end of 19 century that pathologists began to recognize AS as an inflammatory disease, after many years of research in the new field of vascular biology by a number of groups, notably the one by Libby.
Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12 869 patients.
The use of colchicine in patients with CAD is safe and efficacious for MACCE prevention and gastrointestinal DAEs and discontinuation may be prevented with a lower daily dose.


Colchicine and the heart: pushing the envelope.
Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome
Assessment of the local cardiac production of inflammatory cytokines in patients with acute coronary syndromes (ACS), stable coronary artery disease and in controls determined whether acute administration of colchicine inhibits their production, and short-term colchichine administration rapidly and significantly reduces levels of these cytokines.
Colchicine for cardiovascular medicine.
The essential pharmacology is reviewed and potential efficacy and safety of colchicine for new emerging cardiovascular indications are explored.
Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout
In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take col chicine.
Low-dose colchicine for secondary prevention of cardiovascular disease.
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo.
Anti‐Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study
These results suggest a potential benefit of colchicine in ST‐segment‐elevation myocardial infarct, but further clinical trials are necessary to draw secure conclusions, especially considering the fact that the present study was not powered to assess clinical end points.